<?xml encoding="utf-8" ?> Nuvectis Pharma NVCT reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. This ...

What’s New in Clinical Management? / BRAF V600E, cancer, classic HCL, Hairy Cell Leukemia, HCL, Hematology, OncoDaily, ...

Laboratoires Pierre Fabre announces the approval of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for ...

NXP-200 was granted Breakthrough Therapy Designation in China for high-grade glioma, highlighting its potential in difficult-to-treat CNS tumors. The company completed a $150 million follow-on ...

At 8 a.m. ET, Nuvectis will discuss business progress and results for the quarter ended Sept. 30; the webcast replay will remain online at least 30 days.

“A mole on my body—could it be a warning sign?” ... Symptoms that may point to melanoma, a deadly skin cancer ...

Targeting casein kinase II alongside MEK signaling suppresses tumor growth and depletes cancer stem cells in metastatic ...

A new review proposes that the constantly shifting shapes of proteins, not just genetic mutations, drive rapid and reversible ...

Next Generation Tissue Biomarkers Market was valued at USD 3.25 Billion in 2025 and is expected to reach USD 6.89 Billion by ...

Lynch SyndromeGenetic ResultsInherited Risk A positive inherited-risk result means a cancer predisposition—not a cancer ...

A 40-year-old mum is fighting for her life after she went to bed one night and “woke up with Stage 4 bowel cancer”.

A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.